This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding and increased energy. In MDMA-assisted psychotherapy, patients are subjected to two or three multi-hour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress. At the conclusion of this activity, learners will be able to learn about the trials in combined psychotherapy and articulate the need for new treatments of PTSD.
- Provider:American College of Clinical Pharmacology
- Activity Link: https://accp1.org/ACCP1/Events/Event_Display.aspx?EventKey=WEB2022_1
- Start Date: 2022-04-01 05:00:00
- End Date: 2022-04-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all